Windtree Therapeutics

Windtree Therapeutics FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Windtree Therapeutics (WINT) as of Oct 18, 2026 is 280.92 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 66.30 % — a change of 323.74% (higher).

FCF Conversion

280.92 %

YoY

323.74%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Windtree Therapeutics is 2024 280.92 % . FCF Conversion Rate (FCF/EBITDA) of Windtree Therapeutics was 2023 66.30 % . It decreases by 323.74% higher compared to the previous year.

The Windtree Therapeutics FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2017
114.22 USD
Jan 1, 2018
76.90 USD
Jan 1, 2019
90.46 USD
Jan 1, 2020
84.56 USD
Jan 1, 2021
35.40 USD
Jan 1, 2022
49.65 USD
Jan 1, 2023
66.30 USD
Jan 1, 2024
280.92 USD
The Windtree Therapeutics FCF Conversion history
YEARFCF ConversionYoY
280.92 %+323.74%
66.30 %+33.54%
49.65 %+40.24%
35.40 %-58.14%
84.56 %-6.52%
90.46 %+17.63%
76.90 %-32.67%
114.22 %+33.17%
85.77 %+39.33%
61.56 %-35.35%
95.21 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Windtree Therapeutics Stock analysis

What does Windtree Therapeutics do? Windtree Therapeutics Inc., based in Warrington, Pennsylvania, operates in the Health Care sector, specifically within Biotechnology. The company develops and manufactures KL4 surfactant therapies for respiratory diseases, focusing on respiratory distress syndrome in premature infants. Its core product, AEROSURF (lucinactant for inhalation), targets non-invasive treatment of respiratory conditions. Windtree employs 14 full-time staff and is listed on the stock market since 1995. Windtree Therapeutics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Windtree Therapeutics stock

FCF Conversion Rate (FCF/EBITDA) of Windtree Therapeutics is 280.92 % in 2024.

FCF Conversion Rate (FCF/EBITDA) of Windtree Therapeutics changed from 66.30 % to 280.92 %, representing a 323.74% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Windtree Therapeutics since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Windtree Therapeutics with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — Windtree Therapeutics

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — Windtree Therapeutics